IAVI D001
Status:Completed
Phase:I
Principal Investigator(s):
Objective:Evaluate the safety and immunogenicity of TBC-M4 (Modified Vaccinia Ankara (MVA) HIV-1 multigenic subtype C) vaccine in HIV-uninfected, healthy volunteers
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionTBC-M4 (Modified Vaccinia Ankara (MVA) HIV-1 multigenic subtype C)
Mode of Delivery
ARMsExperimental
Official Code:
IAVI D001
Trial Sponsors:
Tuberculosis Research Centre (TRC)
Start Date
End Date
none
none
Enrollment:32
Age range:
↔
any
Population:Cisgender Men, Cisgender Women